Poland – Pharmaceutical products – ZP/CZD/097/26 Supply of medicinal products – 12 packages.

Opportunity description

The subject of the contract is the supply of medicinal products divided into 12 packages, under the terms specified in the draft contract provisions, in quantities resulting from current needs and within the time limits resulting from the concluded contract. The Contracting Authority permits the submission of tenders for individual packages, in which case the contractor may submit a tender for a selected package or all packages listed in Appendix No. 1 to the SWZ (OPZ). The subject of the contract is the supply of Afliberceptum 40 mg/ml, solution for injection. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is the supply of Methylprednisolonum 1000 mg. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is the supply of Methylprednisolonum – sodium succinate salt, 500 mg. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is a conjugate vaccine against meningococci of groups A, C, W-135 and Y. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is a pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed), suspension for injection x 1 pre-filled syringe. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is a pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed), for use in children from 6 weeks of age, 1 x 0.5 ml. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is the supply of Valganciclovirum 50 mg/ml, powder for the preparation of 88 ml of oral solution. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is Tigecyclinum 50 mg x 10 vials. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is: 1. Biotinum 5 mg x 30 tablets 2. Ciprofloxacin 3 mg/ml, eye drops, 5 ml 3. Fludrocortisonum + Gramicidinum + Neomycinum, eye and ear drops, 5 ml 4. Lidocainum hydrochloricum 2% x 10 ampoules of 2 ml each 5. Naloxonum 400 mcg/ml x 10 ampoules, solution for injection 6. Phenytoinum 100 mg x 60 tablets 7. Phytomenadionum 10 mg x 30 coated tablets 8. Propranololum 40 mg x 50 tablets 9. Tropicamidum 1%, eye drops, pack of 2 x 5 ml. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is: 1. Adenosinum 3 mg/ml x 6 vials of 2 ml each 2. Amiodaronum 200 mg x 30 tablets 3. Natrii valproas + Acidum valproicum 100 mg x 30 sachets, prolonged-release granules 4. Natrii valproas + Acidum valproicum 250 mg x 30 sachets, prolonged-release granules 5. Natrii valproas + Acidum valproicum 500 mg x 30 sachets, prolonged-release granules 6. Natrii valproas + Acidum Valproicum 200 mg + 87 mg x 30 prolonged-release tablets 7. Natrii valproas + Acidum Valproicum, 333 mg + 145 mg x 30 prolonged-release tablets 8. Natrii valproas, 288.2 mg/5 ml, 1 bottle of 150 ml, oral solution 9. Natrium valproicum 400 mg/4 ml x 1 vial of 4 ml 10. Teicoplaninum 200 mg x 1 vial 11. Teicoplaninum 400 mg x 1 vial. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is: 1. Calcium polystyrene sulfonate 300 g 2. Sodium polystyrene sulfonate, pack of 454 g, powder for oral use or for the preparation of a rectal suspension. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. The subject of the contract is: 1. Alprostadilum 0.5 mg/ml x 5 ampoules 2. Clindamycinum 150 mg x 16 capsules 3. Methylprednisoloni acetas 40 mg/ml x 1 vial, suspension for injection 4. Methylprednisolonum – sodium succinate salt, 125 mg; powder and solvent for solution for injection x 1 vial + solvent 5. Voriconazolum 40 mg/ml, powder for oral suspension, 45 g bottle. Detailed information on the scope is contained in the price form, Appendix No. 5 to the SWZ. Procedure: open. Estimated value: 1,140,110.37 PLN. Review the original TED notice for the complete requirement, lots, amendments and attachments.